Breast BB-1701-G000-205

An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an Anti-human Epidermal Growth Factor Receptor 2 (Anti-HER2) Antibody-drug Conjugate (ADC), in Previously Treated Subjects With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

Description

The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the efficacy of BB-1701 at RD in the selected population(s) of breast cancer (BC).

Sponsor: Eisai Inc.

Principal Investigator: Dr. Christian Schultheis

EMAIL US ABOUT THIS TRIAL

Back To Clinical Trials NCI Database Entry